Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04652518 · ClinicalTrials.gov registry record · Phase 2
LYT-100 in Post-acute COVID-19 Respiratory Disease
A Phase 2 study, sponsored by PureTech.
- Terminated
- Registry status
- Phase 2
- Development phase
- 185
- Enrollment target
NCT04652518 is a Phase 2 study that was terminated before completion, run by PureTech. The registered enrollment target is 185 participants.
The verdict
NCT04652518, a Phase 2 study, was terminated before completion, sponsored by PureTech.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 185 participants
- Enrollment target
Study Summary
This study is being conducted in two parts, A and B. Part A is a randomized, double-blind, parallel arm study to evaluate the safety and efficacy of LYT-100 compared to placebo in adults with post-acute COVID-19 respiratory complications. Part B is an Open Label Extension (OLE) study for patients who complete Part A.
Interventions
- OTHER Placebo
- DRUG LYT-100
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 185 participants |
| Start Date | 2020-12-11 |
| Est. Completion | 2022-07-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04652518
The ClinicalTrials.gov registry entry for NCT04652518 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 185 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PureTech, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04652518 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04652518 about?
NCT04652518 is a clinical study titled "LYT-100 in Post-acute COVID-19 Respiratory Disease". This study is being conducted in two parts, A and B. Part A is a randomized, double-blind, parallel arm study to evaluate the safety and efficacy of LYT-100 compared to placebo in adults with post-acute COVID-19 respiratory complications. Part B is an Open Label Extension (OLE) study for patients wh...
What is the current status of trial NCT04652518?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 185 participants. The study started on 2020-12-11. Estimated completion is 2022-07-18.
What interventions are being tested in trial NCT04652518?
The interventions under investigation include: Placebo (OTHER), LYT-100 (DRUG).
Who is sponsoring clinical trial NCT04652518?
This trial is sponsored by PureTech, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.